Lilly beats forecast, cuts costs before Cymbalta fadesBy Ransdell Pierson (Reuters) - Eli Lilly and Co reported higher-than-expected quarterly earnings on Wednesday as it slashed costs ahead of generic competition later this year for its biggest product, antidepressant Cymbalta, and raised its 2013 profit view on plans for more streamlining. Shares of Lilly rose almost 3 percent as investors viewed the cost containment for research, marketing and other expenses in the second half of this year as an important move. ...
Source: Lilly beats forecast, cuts costs before Cymbalta fades (http://news.yahoo.com/lilly-beats-forecast-helped-drugs-soon-face-generics-104322616.html)